Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
LUSEDRA is an intravenous small-molecule solution approved by the FDA in December 2008 as an NDA. The drug's specific indication, mechanism of action, and pharmacologic class are not currently disclosed in available data. Patient eligibility and clinical use require review of prescribing information.
Approaching loss of exclusivity with moderate competitive pressure (30/100); brand team likely focused on lifecycle management and retention strategies rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
Lusedra (Fospropofol Disodium) for Minimal to Moderate Sedation for Regional Anesthesia Block Prior to Orthopedic Surgery
A Study to Characterize Pharmacokinetics (PK) and Pharmacodynamics (PD) of LUSEDRA® Administered as Continuous Infusion or Bolus Compared With Continuous Infusion of Propofol Injectable Emulsion
A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure
A Dose-ranging Study to Evaluate the Safety and Efficacy of LUSEDRA (Fospropofol Disodium) as an Intravenous Sedative for Diagnostic or Therapeutic Colonoscopy in Adult Special Populations
Worked on LUSEDRA at Eisai? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LUSEDRA presents limited career opportunity with zero linked job openings and approaching loss of exclusivity. Roles on this product typically involve defensive commercial strategies, managed care negotiations, and transition planning rather than growth-oriented expansion.